Effect of Pamidronate on Osteoporosis in Patients with β-Thalassemia Major

Journal Title: Iranian Journal of Blood and Cancer - Year 2014, Vol 6, Issue 3

Abstract

Background: β-thalassemia major is a hereditary life threatening anemia which requires regular blood transfusion. Clinical symptoms of the disease are growth retardation, pallor, jaundice and skeletal alternations. The variety of bone disease in thalassemia major is manifested by diffuse bone pain or deformity, spontaneous and pathologic fractures and osteopenia or osteoporosis. This study aimed to evaluate the effect of Pamidronate on beta thalassemia major induced osteoporosis. Patients and Methods: This cross sectional study was conducted on 20 patients with β-thalassemia major with osteoporosis. Patients received Pamidronate injections (30 mg in equal intervals of one month) for one year. At the beginning and the end of study period (after twelve months of treatment) patients’ BMD and Z score of lumbar spine and Hip were determined. Results: The mean baseline BMD of lumbar spine and hip among patients were 097/0±720/0(gr/cm²) and 083/0±684/0 (gr/cm²) respectively which at the end of the study these numbers reached to 100/0±783/0(gr/cm²) (p<0.001) and 097/0±713/0(gr/cm²) (p=0.015) respectively. The mean baseline Z score of lumbar spine and hip for patients were /0±98/2-956 and 727/0±96/1- before treatment (one full year of treatment) that reached 886/0±44/2- (p=0.001) and 856 /0±47/1- (p=0.003) respectively. The baseline alkaline phosphatase was 94/89±85/385 µg/dl and after treatment this value decreased to 66/113±95/251µg/dl (p<0.001). Conclusion: The Pamidronate is effective in increasing the bone mineral density and improving the osteoporosis condition in patients with β-thalassemia major. Keywords: Osteoporosis, BMD (Bone Mineral Density), β-thalassemia major, Pamidronate.

Authors and Affiliations

Majid Naderi, Zahra Zakeri, Akbar Dorgalaleh, Shaban Alizadeh, Shadi Tabibian, Taregh Bamedi

Keywords

Related Articles

Carcinosarcoma of Stomach with Chondroblastic Differentiation: A Rare Case and Review of Literature

Gastric carcinosarcoma is a rare cancer of adults with poor prognosis compared with other gastric malignancies. To the best of our knowledge, the present report is the first case of gastric carcinosarcoma with chondrobla...

Iron Stores in Male Blood Donors in Tehran Regional BloodTransfusion Center

Background: Iron deficiency and its related anemia, which is the world’s most widespread nutritional deficiency, can be one of the possible consequences of regular blood donation. This research was carried out to compare...

Minor Histocompatibility Antigen HA-1 Frequency and Acute GVHD in Some Hematopoietic Stem Sell Transplanted Iranian Patients

Background: It is suggested that HA-1 mismatching among hematopoietic stem cell transplanted recipients-donors is associated with acute graft-versus-host disease (aGVHD). So the aim of this study was to evaluate HA-1 fre...

Effects of Recombinant Urate Oxidase (Rasburicase) and Allopurinol for Prophylaxis and Treatment of Hyperuricemia in Patients with Leukemia and Lymphoma

Background: Efficacy of rasburicase in pediatric patients with leukemia and lymphoma is proved. This study aims to weigh efficacy and safety of rasburicase versus more conventional therapy, allopurinol, and to compare th...

A Glance at the Cost of Chelation Therapy with Desferal and Exjade in Iran

Background: Thalassemia is a series of hemoglobinopathies in which the production of perfect hemoglobin is completely or partially suppressed. Using injectable iron chelators have been dominating treatment for the iron o...

Download PDF file
  • EP ID EP364651
  • DOI -
  • Views 103
  • Downloads 0

How To Cite

Majid Naderi, Zahra Zakeri, Akbar Dorgalaleh, Shaban Alizadeh, Shadi Tabibian, Taregh Bamedi (2014). Effect of Pamidronate on Osteoporosis in Patients with β-Thalassemia Major. Iranian Journal of Blood and Cancer, 6(3), 149-153. https://europub.co.uk/articles/-A-364651